A post hoc analysis of subgroup outcomes and creatinine in the phase III clinical trial (EMPOWER) of dexpramipexole in ALS

Journal Club: Comparison of symptomatic and asymptomatic persons with Alzheimer disease neuropathology

(2014) J. R. Brosch et al.   NEUROLOGY

Dexpramipexole versus placebo for patients with amyotrophic lateral sclerosis (EMPOWER): a randomised, double-blind, phase 3 trial

(2013) Merit E Cudkowicz et al.   LANCET NEUROLOGY

Lithium in patients with amyotrophic lateral sclerosis (LiCALS): a phase 3 multicentre, randomised, double-blind, placebo-controlled trial

(2013)   LANCET NEUROLOGY

Controversies and priorities in amyotrophic lateral sclerosis

(2013) Martin R Turner et al.   LANCET NEUROLOGY

The changing scene of amyotrophic lateral sclerosis

(2013) Wim Robberecht et al.   NATURE REVIEWS NEUROSCIENCE

Pearls and Oy-sters: Tuberculous meningitis: Not a diagnosis of exclusion

(2013) A. C. Jongeling et al.   NEUROLOGY

Design and Initial Results of a Multi-Phase Randomized Trial of Ceftriaxone in Amyotrophic Lateral Sclerosis

(2013) James D. Berry et al.   PLoS One

Infrastructure resources for clinical research in amyotrophic lateral sclerosis

(2013) Alexander V. Sherman et al.   Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration

Deciphering amyotrophic lateral sclerosis: What phenotype, neuropathology and genetics are telling us about pathogenesis

(2013) John Ravits et al.   Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration

The Combined Assessment of Function and Survival (CAFS): A new endpoint for ALS clinical trials

(2013) James D. Berry et al.   Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration

Prognostic categories for amyotrophic lateral sclerosis

(2012) William J. Scotton et al.   Amyotrophic Lateral Sclerosis

Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS study

(2012) Virginia Devonshire et al.   LANCET NEUROLOGY

Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis

(2012) Robert J. Fox et al.   NEW ENGLAND JOURNAL OF MEDICINE

Biochemical alterations associated with ALS

(2011) Kay A. Lawton et al.   Amyotrophic Lateral Sclerosis

Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis

(2011) Gavin Giovannoni et al.   LANCET NEUROLOGY

The effects of dexpramipexole (KNS-760704) in individuals with amyotrophic lateral sclerosis

(2011) Merit Cudkowicz et al.   NATURE MEDICINE

Toward more efficient clinical trials for amyotrophic lateral sclerosis

(2009) Merit E. Cudkowicz et al.   Amyotrophic Lateral Sclerosis

Prognostic factors in ALS: A critical review

(2009) Adriano Chiò et al.   Amyotrophic Lateral Sclerosis

Subgroup Analysis of Trials Is Rarely Easy (SATIRE): a study protocol for a systematic review to characterize the analysis, reporting, and claim of subgroup effects in randomized trials

(2009) Xin Sun et al.   Trials

Biomarkers in amyotrophic lateral sclerosis

(2008) Martin R Turner et al.   LANCET NEUROLOGY

Subcutaneous IGF-1 is not beneficial in 2-year ALS trial

(2008) E. J. Sorenson et al.   NEUROLOGY

Designing Clinical Trials in Amyotrophic Lateral Sclerosis

(2008) Jeremy M. Shefner   Physical Medicine and Rehabilitation Clinics of North America